首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5502篇
  免费   298篇
  国内免费   36篇
耳鼻咽喉   142篇
儿科学   136篇
妇产科学   45篇
基础医学   715篇
口腔科学   137篇
临床医学   319篇
内科学   1420篇
皮肤病学   81篇
神经病学   633篇
特种医学   140篇
外科学   912篇
综合类   21篇
预防医学   140篇
眼科学   71篇
药学   408篇
中国医学   10篇
肿瘤学   506篇
  2023年   26篇
  2022年   63篇
  2021年   135篇
  2020年   65篇
  2019年   94篇
  2018年   110篇
  2017年   88篇
  2016年   89篇
  2015年   100篇
  2014年   140篇
  2013年   157篇
  2012年   270篇
  2011年   324篇
  2010年   176篇
  2009年   144篇
  2008年   249篇
  2007年   291篇
  2006年   289篇
  2005年   254篇
  2004年   293篇
  2003年   252篇
  2002年   234篇
  2001年   148篇
  2000年   184篇
  1999年   177篇
  1998年   76篇
  1997年   55篇
  1996年   63篇
  1995年   45篇
  1994年   48篇
  1993年   58篇
  1992年   117篇
  1991年   87篇
  1990年   104篇
  1989年   121篇
  1988年   95篇
  1987年   81篇
  1986年   78篇
  1985年   65篇
  1984年   49篇
  1983年   35篇
  1982年   24篇
  1981年   16篇
  1980年   23篇
  1979年   38篇
  1978年   20篇
  1977年   28篇
  1975年   17篇
  1968年   17篇
  1966年   16篇
排序方式: 共有5836条查询结果,搜索用时 46 毫秒
91.
92.
93.
94.
Fixed drug eruption is a common cutaneous adverse reaction in young patients with a characteristic clinical appearance. However, the diagnosis and identification of the substance may be difficult if food or food additives provoke the fixed eruption. A 26‐year‐old man had a history of two episodes of cutaneous erythema with residual pigmentation. Close examination of the history including his diet in addition to an oral challenge test and patch testing led to the diagnosis of fixed eruption secondary to quinine in tonic water. We examined for the presence of quinine in commercially available brands of tonic water using ultraviolet A and irradiation and high‐performance liquid chromatography. Both Schweppes and CANADA DRY brands of tonic water emitted fluorescent light upon ultraviolet A irradiation, and contained quinine at concentrations of 67.9 and 61.3 mg/L, respectively. Quinine contained in some tonic waters may trigger fixed eruption.  相似文献   
95.

Background

In 1999, the Japanese Orthopaedic Association decided to develop a new Cervical Myelopathy Evaluation Questionnaire (JOACMEQ). The final version of the JOACMEQ, comprising 24 questions and five domains (cervical spine function (CF); upper extremity function (UF); lower extremity function (LF); bladder function (BF); and quality of life (QOL)), was established after three nationwide investigations. The fourth investigation, reported in this paper, was performed to confirm the responsiveness of the questionnaire.

Methods

A total of 137 patients with cervical myelopathy were included in the study. Each patient was interviewed twice using the JOACMEQ before and after treatment. At the second interview, the patients self-rated their condition in five domains for “worse,” “somewhat worse,” “no change,” “somewhat better,” or “better,” and these scores were defined as the external assessment rating. The difference of the points in five domains between the first and the second interview was calculated against each external assessment. Based on the results, substantial clinical benefit (SCB) thresholds for the JOACMEQ were determined.

Results

The statistically significant median values of the acquired points were 17.5 for CF, 16.0 and 21.0 for UF, 27.0 and 20.5 for LF, 13.0 for BF, and 29.0 for QOL. After consideration of the results, the committee decided that an acquired point ≥20 could be interpreted as representing an SCB threshold for the JOACMEQ.

Conclusion

We have concluded that a treatment can be judged to be effective for a patient if 1) The patient give all answers for the questions necessary to calculate the functional score of a domain and an increase of ≥20 points is obtained for that score, or 2) The functional score after treatment is > 90 points even if the answer for the unanswered questions was supposed to be the worst possible choice.  相似文献   
96.
97.
98.
Journal of Gastroenterology - A correction to this paper has been published: https://doi.org/10.1007/s00535-021-01786-z  相似文献   
99.
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号